, Volume 6, Supplement 1, pp 61–62 | Cite as

The Future Research Agenda

A View from the Pharmaceutical Industry
  • Catherine V. Barr
Discussant’s Summary


As a responsible partner in healthcare systems, the pharmaceutical industry hopes to see a research agenda on pharmaceutical issues that will provide more information on trends in healthcare reform affecting medicines. Urgent questions include whether some forms of cost containment are harming innovation and the quality of care, and what constructive alternatives to policies such as reference pricing can the industry offer?


Reference Price Price Competition Cost Containment Health Reform Reimbursement System 


  1. 1.
    Hoffmeyer U. The economics of health reform: a prototype. PharmacoEconomics 1994; 6 Suppl. 1: 39–41PubMedCrossRefGoogle Scholar
  2. 2.
    Redwood H. Public policy trends in drug pricing and reimbursement in the European Community. PharmacoEconomics 1994; 6 Suppl. 1: 3–10PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 1994

Authors and Affiliations

  • Catherine V. Barr
    • 1
  1. 1.International Pharmaceuticals Group, Pfizer IncNew YorkUSA

Personalised recommendations